Experience of chloroquine use in COVID-19 patients

Authors

Keywords:

coronavirus infections, anti-infectives, chloroquine, observational studies as a subject, result of treatment

Abstract

Introduction: COVID-19 is a pandemic without specific treatment at the time of this study. Chloroquine has been one of the drugs applied due to its in vitro antiviral effects.

Objective: To identify the effect of chloroquine on patients treated with COVID-19 in relation to humoral parameters, hospital stay, complications and mortality.

Methods: Retrospective observational study, with 181 positive cases of SARS-CoV-2, divided into two study groups according to use. Group 1 (n = 154) those treated with chloroquine and group 2 (n = 27) those who did not receive it. Personal pathological history, antimicrobial treatment, humoral parameters were identified at admission and between the sixth and eighth day of admission, hospital stay, complications and death. The squared ji test, Mann-Whitney U test and Wilcoxon's sign rank test were used according to convenience.

Results: Group 2 had a higher proportion of arrhythmia (n = 4; 14.8%), dementia (n = 2; 7.4%), other background (n = 12; 44.4%) and higher values of leukocytes (m = 7.25 x 109/L; RIC: 4.55 – 9.55 vs. m = 4.8 x 109/L; RIC: 3.95 – 6.8) and alkaline phosphatase (m = 94 U/L; RIC: 84 – 125 vs. m = 83 U/L; RIC: 66 – 98) that group 1 upon admission. All humoral parameters on the sixth and eighth days, hospital stay, and proportions of complications and death in both groups were similar.

Conclusions: No effect attributable to the use of chloroquine on patients with COVID-19 was identified in terms of humoral parameters, hospital stay, frequency of complications or mortality.

Downloads

Download data is not yet available.

Downloads

Published

2022-09-19

How to Cite

1.
Suárez Díaz T, González Tabares R, Acosta González FA, Oliva Villa E, Rodríguez Reyes SF, Cabeza Echevarría I, et al. Experience of chloroquine use in COVID-19 patients. Rev Cubana Salud Pública [Internet]. 2022 Sep. 19 [cited 2025 Feb. 5];48(3). Available from: https://revsaludpublica.sld.cu/index.php/spu/article/view/2772

Issue

Vol. 48 No. 3 (2022): julio-septiembre

Section

Research

License

Aviso de derechos de autor/a

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:

  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).